Contents

Contributors xiii

1. Physiology of erythropoiesis 1
   U. Testa

2. Biology of EPO and EPO-receptor 67
   C. Lacombe and P. Mayeux

3. The role of erythropoietin receptor expression on tumor cells 81
   J. Fandrey

4. Problems associated with erythropoietin receptor determination on tumor cells 103
   A. Österborg

5. Definition, classification and characterization of anemia in cancer 117
   M. R. Nowrousian

6. Pathophysiology of anemia in cancer 149
   M. R. Nowrousian

7. Prevalence and incidence of anemia and risk factors for anemia in patients with cancer 189
   H. Ludwig

8. Significance of anemia in cancer chemotherapy 207
   M. R. Nowrousian

9. Incidence and impact of anemia in radiation oncology 249
   J. Dunst and M. Molls

10. Relationship between hemoglobin levels and tumor oxygenation 265
    P. Vaupel, A. Mayer and M. Höckel
11. Tumor hypoxia and therapeutic resistance
   P. Vaupel and M. Höckel
   283

12. Symptoms of anemia
   R. Pirker
   307

13. Impact of anemia and red blood cell transfusion on organ function
   M. R. Nowrousian
   317

14. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients
   Z. Butt and D. Cella
   369

15. When to use red blood cell transfusions in cancer patients with solid tumours?
   J. K. Jacob and P. J. Barrett-Lee
   393

16. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations
   W. Jelkmann
   407

17. Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma
   A. Österborg
   433

18. rhEPO in anemic patients with solid tumors and chemotherapy – efficacy and safety
   M. R. Nowrousian
   449

19. Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia
   G. H. Lyman and J. Glaspy
   509

20. Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia
    E. Hellström-Lindberg
    531

21. Prediction of response to rhEPO in the anemia of cancer
    Y. Beguin and G. Van Straelen
    541

22. rhEPO in hematopoietic stem cell transplantation
    G. Van Straelen and Y. Beguin
    583
Contents

23. Treatment of anemia with rhEPO in radiation oncology  
   J. Dunst 615

24. Recombinant human erythropoietin in pediatric oncology  
   C. Hastings and J. Feusner 635

25. rhEPO in surgical oncology  
   M. J. Fontaine and L. T. Goodnough 663

26. Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy  
   L. T. Goodnough 679

27. Are there risks for use of iron in cancer patients?  
   P. Gascón 703

28. Metabolic and physiologic effects of rhEPO in anemic cancer patients  
   K. Lundholm and P. Daneryd 713

29. Effects of rhEPO on quality of life in anemic cancer patients  
   S. Chowdhury, J. F. Spicer, and P. G. Harper 729

30. Thrombosis during therapy with erythropoiesis stimulating agents in cancer  
   J. Glaspy 745

31. The effect of rhEPO on survival in anemic cancer patients  
   T. J. Littlewood 759

32. From bench to bedside: Neuroprotective effects of erythropoietin  
   H. Ehrenreich and C. Bartels 771

33. rhEPO in patients with anemia and congestive heart failure  
   D. S. Silverberg, D. Wexler, A. Iaina, S. Steinbruch,  
   Y. Wollman, and D. Schwartz 793

34. Cost-effectiveness of treating cancer anaemia  
   P. Cornes 813

Addendum 851

Index 853
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
Scientific and Clinical Aspects of Anemia in Cancer
Nowrousiyan, M.R. (Ed.)
2008, XVIII, 866 p., Hardcover
ISBN: 978-3-211-25223-9